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Background: Lipid-modifying drug therapy (LMDT) is recommended in all patients having coronary or noncoronary
atherosclerotic disease. However, the effect of LMDT after abdominal aortic aneurysm (AAA) repair, especially in the
absence of other atherosclerotic manifestations, is unclear. We examined the distribution of prevalence of LMDT among
patients undergoing AAA repair and its effect on survival in the presence and absence of other atherosclerotic diseases.
Methods:We identiﬁed patients treated at University of Alabama at Birmingham between 1985 and 2010 who had a prior
AAA repair. Information was collected from health system medical charts, medical communication, and national death
indices. We assessed the predictors of prevalence of LMDT by univariate analysis using t-test for continuous and c2 test
for categorical variables, and then performed multivariate logistic regression. The survival was determined using Kaplan-
Meier plots, and adjusted hazard ratios were calculated using Cox proportion regression.
Results: A total of 2063 patients underwent AAA repair procedure. Of these, 9% were African-American, and 20% were
female. Thirty-ﬁve percent received LMDT, and 32% died during the follow-up period of up to 240 months. Signiﬁcant
predictors for being on LMDT included white race (odds ratio [OR], 1.6; 95% conﬁdence interval [CI], 1.1-2.2),
presence of other atherosclerotic disease or diabetes (OR, 2.4; 95% CI, 1.9-3.0), hypertension (OR, 4.0; 95% CI, 3.1-5.2),
smoking (OR, 1.6; 95% CI, 1.2-2.1), and endovascular AAA repair (OR, 1.9; 95% CI, 1.5-2.3). LMDT was associated
with improved survival (hazard ratio, 0.6; 95% CI, 0.5-0.8) after controlling for traditional risk factors, diabetes, and
other atherosclerotic diseases.
Conclusions: LMDT after AAA is associated with an increased survival compared with patients who were not using drug
therapy for dyslipidemia. Aggressive management of dyslipidemia should be considered in all patients undergoing AAA
repair irrespective of other atherosclerotic disease status and risk factor proﬁle. (J Vasc Surg 2013;58:355-63.)Each year, approximately 57,000 hospital discharges
and nearly 19,000 deaths occur in individuals with abdom-
inal aortic aneurysms (AAA) in the U.S.1 The 2005 collab-
orative report from the American College of Cardiology
Foundation, American Heart Association, Society for
Vascular Surgery, Society for Cardiovascular Angiography
and Interventions, Society for Vascular Medicine and
Biology, and Society for Interventional Radiology (here-
after, “PAD task force”) on practice guidelines for the
management of patients with peripheral arterial disease
(PAD; lower extremity, renal, mesenteric, and abdominal
aortic) deﬁnes AAA when the anteroposterior diameter of
the aorta is more than or equal to 3.0 centimeters.2 The
prevalence of small AAA (3.0-4.9 cm in diameter) ranges
from 1.3% in younger men (aged 45-54 years) to 12.5%
in older men (aged 75-84 years), and 0% to 5.2% in thethe Section of Vascular Surgery and Endovascular Therapy, University
Alabama at Birmingham.
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diameter) expand more rapidly than small AAA, and carry
a higher risk for rupture that may be associated with death
rates as high as 90%.1,2
Lipid-modifying drug therapy (LMDT) is recommen-
ded in all patients having coronary heart disease or having
clinical manifestations of any noncoronary forms of athero-
sclerotic disease.2-4 Prescription of statin as a cholesterol
lowering agent for protection from myocardial infarction,
stroke, and cardiovascular death in patients with PAD
was introduced as a performance measure in the 2010
collaborative report from the PAD task force.5 However,
the effect of LMDT on survival after AAA repair, especially
in the absence of other atherosclerotic manifestations, is
unclear. In a recently conducted systemic review and
meta-analysis of the effects of statins on AAA, Twine
et al6 were unable to identify conclusive evidence for reduc-
tion in mortality after rupture,7 improved survival free from
AAA repair,8 and cardiovascular speciﬁc mortality9; mostly
because these outcomes were either not reported separately
or were available only in single studies. They also
concluded that the statins had no effect on AAA expan-
sion.6 Higher levels of triglycerides and low-density lipo-
protein (LDL) cholesterol were not associated with
increased risk of AAA in an Australian study.10
Possible biological mechanisms for this relationship
seem to be multifaceted. AAA formation involves chronic
inﬂammation, depletion of smooth muscle cells, and
increased degradation of aortic wall proteins by matrix met-
alloproteinases (MMP).11,12 An imbalance between MMP355
Fig 1. Identiﬁcation of eligible study participants.
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disease.13 Statins have pleiotropic effects, including anti-
inﬂammatory activity, apart from their cholesterol-
lowering action.14 There is some observational evidence
that statins reduce MMP concentrations in the AAA
wall,13,15,16 including few case-series demonstrating the
association between statin prescription and reduced AAA
growth.17-19 However, a recent randomized controlled
trial conducted by Rahman et al found that statin use
does not inﬂuence the levels of MMP or their inhibitors
in AAA wall.20 Moreover, statin use was associated with
increased risk of AAA in a recent large population-based
observational (Tromsø) study.21 The Tromsø study also
concludes that atherosclerosis may not be a causal event
in AAA but develops in parallel with or secondary to aneu-
rysm.22 As a result of lack of substantial evidence, the 2005
Society for Vascular Surgery practice guidelines for the
management of patients with peripheral arterial disease
suggest that it remains to be determined whether statin
therapy could be useful for prevention or treatment of
AAA.2
The University of Alabama at Birmingham Vascular
registry provides this unique opportunity to study the
short- and long-term effects of LMDT on AAA repair.
We agree with Twine et al that it is relatively unlikely to
have a randomized controlled trial in the future to speciﬁ-
cally answer the question of whether all patients with AAA
should be on LMDT for cardiovascular protection.6 We
examined the distribution of LMDT prevalence among
patients undergoing AAA repair and its effect on survival
from aneurysm-related mortality, cardiovascular-speciﬁc
mortality, and all-cause mortality in the presence and
absence of diabetes and other atherosclerotic diseases.
METHODS
Study design and participants. We identiﬁed index
atherosclerotic AAA repair procedures performed between
1985 and 2010 at the University of Alabama at Birming-
ham vascular surgery service from a prospectively main-
tained registry (Fig 1). Procedures performed due to
nonatherosclerotic reasons such as trauma, mycotic
aneurysms, and collagen vascular diseases were excluded.
Information was collected from health system medical
charts, including discharge summaries, operative reports,
laboratory data, outpatient clinic visits, medical commu-
nications, and Social Security Death Index (SSDI) web-
site. Demographic factors included age, gender, and race.
Prior to surgery, patients were screened for risk factors,
including smoking, coronary artery disease, hypertension,
carotid disease, lower extremity atherosclerotic disease,
chronic pulmonary disease, stroke, diabetes, and renal
dysfunction. The study protocol was reviewed and
approved by the University of Alabama Institutional Re-
view Board.
Deﬁnition of variables. Age was categorized into
10-year intervals of <55, 55-64, 65-74, 75-84, and $85;
racial grouping was either African-American or White.
Smoking was categorized as currently smoking, pastsmoking (but not currently), or never having been
a smoker based upon patients’ history. Coronary artery
disease was deﬁned as patient report, physician diagnosis
report in the medical records or communications, or
a history of myocardial infarction, percutaneous coronary
intervention, or coronary artery bypass grafting. Hyper-
tension was deﬁned as having been previously diagnosed
with hypertension, or treatment with antihypertensive
medications. Carotid and lower extremity atherosclerotic
diseases were identiﬁed through screening of vascular
registry if participants had any clinic visits, hospital admis-
sions, or procedures performed for these vascular condi-
tions. Chronic obstructive pulmonary disease and stroke
were deﬁned as physician diagnosis report in the medical
records or communications, or via imaging evidence.
Diabetes was deﬁned as having been diagnosed with dia-
betes, or treatment with insulin, or on oral anti-diabetic
medications. Treatment with dialysis was used as a surro-
gate for end-stage renal dysfunction. To study the role of
coronary heart disease risk-equivalent as deﬁned in the
Adult Treatment Panel (ATP) III guidelines of the
National Cholesterol Education Program (NCEP), we
created a composite variable as presence of other athero-
sclerotic disease or diabetes. Other atherosclerotic diseases
included coronary artery disease, lower extremity athero-
sclerotic disease, and carotid disease.
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Birmingham vascular surgery service protocol requires
patients to visit the outpatient clinic within 4 weeks after
a major vascular procedure, and every 6 to 12 months
thereafter. In case of a loss to follow-up, the patient’s
primary care provider is contacted by telephone. LMDT
may have been initiated for higher LDL, higher triglycer-
ides, lower high-density lipoprotein cholesterol, or as
a part of NCEP’s ATP III recommendations for the
primary prevention of myocardial infarction and cardio-
vascular death.4 LMDT includes patients taking stains as
well as any lipid-lowering drug therapy other than thera-
peutic lifestyle changes, including ﬁbrates (gemﬁbrozil,
fenoﬁbrate), bile acid sequestrants (cholestyramine, coles-
tipol, and colesevelam), cholesterol absorption inhibitors
(ezetimibe), or nicotinic acid.
Outcomes. Vital status information was ascertained by
reviewing registry records and via SSDI.23 Patients were
censored at the time of death or at the last clinic corre-
spondence to our vascular service in the time-to-event
analyses. Cause of death was determined from the
hospital record for patients who died during follow-up at
University of Alabama Vascular service, and by contacting
relatives and/or primary care provider for those who died
outside of the hospital. Death was classiﬁed as “unknown”
if it was ascertained through SSDI without further infor-
mation or when the cause of death was uncertain. The
main outcomes of the study were all-cause and aneurysm-
related mortality. All deaths within 30 days of aneurysm
repair were considered to be related to the aneurysm. As
part of a sensitivity analysis, deaths due to nonaortic
vascular causes (stroke, carotid, or lower extremity) and
deaths related to cardiac causes (myocardial infarction,
heart failure, arrhythmia, or sudden death) were combined
with aneurysm-related deaths to create a cardiovascular
mortality group.
Statistical analysis. We assessed the predictors of
prevalence of LMDT by univariate analysis using Student
t-test for continuous variables and c2 test for categorical
variables. We then performed multivariable logistic regres-
sion to determine the strength of association for signiﬁcant
variables. The survival was determined using Kaplan-Meier
plots, and adjusted hazard ratios were calculated using Cox
proportion regression. Differences between survival curves
were compared with the log-rank test. In analyses of
aneurysm-related mortality and cardiovascular mortality,
patients who died of nonaneurysmal causes and non-
cardiovascular causes, respectively, were censored at the
time of death. Statistical signiﬁcance was set at an alpha
value of 0.05. All statistical analyses were conducted using
SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
A total of 2629 aortic procedures were performed
between January 1985 and December 2010 at the Univer-
sity of Alabama at Birmingham Vascular Surgery service. Of
these 2629 procedures, 460 were performed on thoracic
aorta for various reasons and were excluded from thecurrent study. We also excluded 104 aortic procedures per-
formed secondarily after primary aortic repair procedure.
Thus, we identiﬁed 2065 index procedures for AAA repair
(Fig 1). Two procedures were excluded because they were
performed in patients younger than 20 years of age; one
was a 6-year-old African American girl who underwent
open AAA repair in 2008, and the other was a 9-year-old
Hispanic boy with a mycotic aneurysm that had been
denied open repair and required an endovascular repair
in 2009.
Of the 2063 patients who underwent index AAA repair
procedure, 35% (n ¼ 726) received LMDT and 32% (n ¼
656) died during the follow-up period of 241 months. In
comparison to patients who did not use LMDT, the
LMDT users were smokers (87% vs 61%; P < .0001) and
more often whites (92% vs 78%; P ¼ .03), and had a higher
prevalence of hypertension (86% vs 48%; P < .0001), dia-
betes (19% vs 8%; P ¼ .0001), and other atherosclerotic
diseases (75% vs 44%; P < .0001; Table). Multivariable
adjusted logistic regression revealed that hypertension
(odds ratio [OR], 4.0; 95% conﬁdence interval [CI], 3.1-
5.2) was the strongest predictor for patients being on
LMDT, followed by presence of other atherosclerotic
diseases or diabetes (OR, 2.4; 95% CI, 1.9-3.0), and endo-
vascular repair (OR, 1.9; 95% CI, 1.5-2.3). White race was
a signiﬁcant predictor for being on LMDT (OR, 1.6; 95%
CI, 1.1-2.2) compared with African Americans, which
supports past reports.24 Smokers were also more likely to
be on LMDT (OR, 1.6; 95% CI, 1.2-2.1) than non-
smokers.
The mean follow-up was 31 months (range, 0 to 241
months). Of the 656 patients (32%) who died during
follow-up, 82 (13%) died due to aneurysm-related causes,
and an additional 49 (7%) died due to cardiac or other
nonaortic vascular causes. Cardiovascular mortality
included aneurysm-related, cardiac, and nonaneurysm-
related vascular mortality (82 þ 49 ¼ 131). Most of the
patients died from causes unrelated to aneurysm or cardio-
vascular disease process. The cause of death was unknown
for patients whose deaths were identiﬁed through SSDI.
Patients who died had a longer mean follow-up compared
with those who did not die (40 months vs 27 months).
Similarly, patients with presence of other atherosclerotic
disease or diabetes had slightly longer mean follow-up
compared with those without them (35 months vs 26
months). However, mean follow-up did not differ by
type of AAA repair procedure (32 months for open repair
vs 31 months for endovascular repair).
LMDT users had signiﬁcantly improved survival from
aneurysm-related mortality at 30 days (98.1 % vs 94.7%),
1 year (98% vs 94.5%), and 5 years (98% vs 94.5%)
compared with nonusers (standard error [SE], <10%;
log-rank P value ¼ .0001; Fig 2, a). There was more
obvious improvement in survival from all-cause mortality
among LMDT users at 30 days (98.1% vs 94.7%), 1 year
(90% vs 84.6%), and 5 years (68.5% vs 51.6%) compared
with nonusers (SE, <10%; log-rank P value < .0001;
Fig 2, c). In sensitivity analysis for cardiovascular mortality,
Table. Baseline characteristics (n ¼ 2063 patients)
Lipid-modifying drug
therapy
P value
No
(n ¼ 1337)
Yes
(n ¼ 726)
No. % No. %
Demographics:
Age
<50 years 100 7.5 23 3.2 .14
51-64 years 275 20.6 160 22.0
65-74 years 568 42.5 331 45.6
75-84 years 345 25.8 197 27.1
>85 years 49 3.7 15 2.1
Male gender 1039 77.7 617 85.0 .26
Race
African-American 131 9.8 58 8.0 .03a
European-American 1048 78.4 664 91.5
Other 158 11.8 4 0.6
Risk factors:
Diabetes 103 7.7 136 18.7 .0001a
Hypertension 639 47.8 625 86.1 <.0001a
Ever smoker 819 61.3 631 86.9 <.0001a
Chronic obstructive
pulmonary disease
283 21.2 162 22.3 .88
Dialysis 34 2.5 26 3.6 .28
Other atheroscleretic
diseases
592 44.3 544 74.9 <.0001a
Coronary artery disease 492 36.8 499 68.7 <.0001a
Stroke 123 9.2 90 12.4 .02a
Carotid disease 36 2.7 35 4.8 .01a
Lower extremity arterial
disease
69 5.2 55 7.6 .03a
Other atheroscleretic
diseases or diabetes
627 46.9 569 78.4 <.0001a
AAA repair type
Open repair 703 52.6 254 35.0 <.0001a
Endovascular repair 634 47.4 472 65.0
AAA, Abdominal aortic aneurysm.
Student t-test used for continuous variables and c2 test used for categorical
variables.
aStatistical signiﬁcance was set at alpha of .05.
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(98.1% vs 94.7%), 1 year (97.7% vs 93.3%), and 5 years
(94.4% vs 90.3%) compared with nonusers (SE, <10%;
log-rank P value ¼ .0003; Fig 2, b). Survival estimates at
different time intervals were obtained through life-table
method. The association between LMDT and mortality
remains unchanged after adjusting for other covariates in
Cox proportional hazard regression. LMDT users had
a 50% reduction in aneurysm-related mortality (HR, 0.5;
95% CI, 0.3-0.9), a 40% reduction in cardiovascular
mortality (HR, 0.6; 95% CI, 0.4-0.9), and a 40% reduction
in all-cause mortality (HR, 0.6; 95% CI, 0.5-0.8) after
adjusting for age, race, gender, type of AAA repair, dia-
betes, hypertension, smoking, and presence of other
atherosclerotic diseases (Fig 3).
Presence of other atherosclerotic disease or diabetes
was not associated with aneurysm-related mortality (HR,
0.8; 95% CI, 0.5-1.3) or cardiovascular mortality (HR,
0.9; 95% CI, 0.6-1.3). However, this association wasmarginal for all-cause mortality (HR, 1.1; 95% CI, 1.0-
1.4). Compared with open AAA repair, endovascular repair
was protective for aneurysm-related mortality (HR, 0.4;
95% CI, 0.2-0.6) and all-cause mortality (HR, 0.7; 95%
CI, 0.6-0.9), but failed to reach statistical signiﬁcance for
cardiovascular mortality (HR, 0.8; 95% CI, 0.5-1.1). White
race was also protective for all three mortality groups:
aneurysm-related (HR, 0.4; 95% CI, 0.2-0.6), cardiovas-
cular (HR, 0.4; 95% CI, 0.3-0.7), and all-cause (HR,
0.7; 95% CI, 0.5-0.9). Age showed a clear linear trend of
increase in all mortality (aneurysm-related, cardiovascular,
and all-cause) with increasing age. Gender, hypertension,
and smoking status were not associated with any of these
mortality groups.
DISCUSSION
Aneurysm-related, cardiovascular, and all-cause mor-
tality rates following AAA repair were signiﬁcantly and
independently improved by LMDT in the present study.
Since ours is not a randomized study, LMDT users were
different from nonusers in clinical characteristics. LMDT
users had a higher prevalence of smoking, diabetes, hyper-
tension, and other atherosclerotic diseases. The association
between LMDT use and reduced mortality remained
consistent after adjustment for demographics, traditional
risk factors, and type of AAA repair.
Evidence-based recommendations on the management
of dyslipidemia and related disorders are published period-
ically by NCEP’s expert panel (ATP). The most recent
revision of these recommendations was published in
2004,4 while the earlier guidelines were published in
1988 (ATP I),25 1993 (ATP II),26 and 2001 (ATP
III).27 According to the most recent guideline, the highest
risk category (10-year risk of hard coronary heart disease
[CHD] event >20%) includes CHD or CHD risk equiva-
lents. Hard CHD events include myocardial infarction and
CHD death. CHD risk equivalents include diabetes and
clinical manifestations of noncoronary forms of atheroscle-
rotic disease (PAD, AAA, stroke, and transient ischemic
attacks of carotid origin). LDL cholesterol goal is <100
mg/dL (<70 mg/dL optional) in this risk category.
However, LMDT beneﬁts even when baseline LDL is
average or normal.28-33 According to this guideline, all of
our registry patients who underwent AAA repair should
receive LMDT. But inclusion of AAA as a CHD risk equiv-
alent is relatively recent, whereas diabetes and atheroscle-
rotic diseases were considered high-risk for hard CHD
event from the very beginning. So, the presence of diabetes
or atherosclerotic disease should be the strongest predictor
of being on LMDT. In our registry, we found that hyper-
tension is the strongest predictor of receiving LMDT.
Despite clearly demonstrated beneﬁts of LMDT for
cardiovascular protection in atherosclerotic diseases, its
effect on pathophysiology of AAA still remains question-
able. AAA and atherosclerosis are associated with each
other.34,35 However, it is unclear whether atherosclerosis
causes AAA or vice versa.35,36 In experimental models,
aneurysm development preceded the atherosclerotic
Fig 2. a, Survival from aneurysm-related mortality (n ¼ 82). b, Survival from cardiovascular mortality (n ¼ 131).
c, Survival from all-cause mortality (n ¼ 656). LMDT, Lipid-modifying drug therapy; SE, standard error.
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Fig 3. Multivariable adjusted hazard ratios with 95% conﬁdence intervals (CIs) from Cox proportional hazard
regression. EVAR, Endovascular repair; LMDT, lipid-modifying drug therapy; OADD, other atherosclerotic diseases or
diabetes.
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parallel with atherosclerosis and is not causal.22 Our results
demonstrate signiﬁcant beneﬁts in aneurysm-related
mortality by LMDT even after adjustment for diabetes
and atherosclerotic diseases. Possible mechanisms of this
effect apart from atherosclerosis is unclear. Some studies
showed that LMDT reduced MMP concentrations in the
AAA wall,13,15,16 including a few case series demonstrating
the association between statin prescription and reduced
AAA growth.17-19 Statins attenuates plaque inﬂammation,
inﬂuence plaque stability,38 and affect the coronary and
non-coronary circulation.39 Statins suppress the develop-
ment of AAA in mice40,41 and reduce the risk of AAA
rupture in humans.8 Clear understanding of possible biolog-
ical mechanisms of this effect still warrants further
investigation.
Patients treated with endovascular repair are more
likely to receive LMDT compared with patients treated
with open repair in our registry. One can expect this, as
LMDT in patients with symptomatic AAA is recommended
by recently published ATP III guidelines, and endovascular
repair is a relatively newer minimally-invasive alternative
treatment for AAA. Some studies showed no survival
beneﬁt by type of repair procedure,42 while others showed
early survival beneﬁt by endovascular repair, which was lostafter 1 to 3 years.43,44 However, we earlier showed that
endovascular repair has survival beneﬁt over open repair
in an observational retrospective analysis for up to 9 years
of follow-up.45 This does not account for the effect of
LMDT on mortality in adjusted analysis. LMDT and endo-
vascular repair both independently improved survivals in
our study.
Our study has several limitations to consider. Informa-
tion regarding LMDT was collected dichotomously in the
UAB vascular registry, with two possible entries being
‘YES’ or ‘NO.’ Therefore, we did not have information
on which drug they were receiving and whether the drug
therapy was effective in controlling their lipid levels or
not. However, a recent revision of ATP III guideline
suggests to correct all lipid disorders aggressively and not
only LDL. It also suggests considering combinations of
other drugs like ﬁbrates and niacin with statins to achieve
optimum lipid control. Since we do not have actual lipid
levels in our registry, we were unable to comment on
control of lipids. However, dyslipidemia in non-LMDT
users is unlikely in our registry due to follow-up, and
uncontrolled lipids in LMDT users would introduce bias
towards null, which would ultimately underestimate the
protective effect of LMDT. We also did not have informa-
tion regarding when the LMDT was initiated with regard
JOURNAL OF VASCULAR SURGERY
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the day of, or after AAA repair procedure. While the
mortality beneﬁt of LMDT is greatest in those patients
who are on longer duration of treatment, beneﬁts were
noted in patients recently started on LMDT as well.46
Because of the nature of this study, we do not have infor-
mation about compliance for LMDT use. However,
noncompliance of LMDT would introduce bias towards
null and underestimate the protective effect of LMDT.
Finally, we were unable to ascertain cause of death when
a patient was lost to follow-up or when death was identiﬁed
through SSDI. Nevertheless, the consistent survival beneﬁt
of LMDT across all mortality outcomes is noteworthy. As
in all observational studies, caution in ascribing the
observed effects to LMDT is prudent.
In conclusion, LMDT is independently associated with
improved survival from aneurysm-related mortality, cardio-
vascular mortality, and all-cause mortality in patients who
have completed AAA repair after adjusting for traditional
risk factors, diabetes, and other atherosclerotic diseases.
Aggressive management of dyslipidemia should be consid-
ered in all patients undergoing AAA repair irrespective of
their other atherosclerotic disease status and risk factor
proﬁle.
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PVSS for the privilege of discussing this paper, and I would like to
commend the research done by the group at Alabama looking at
the value of statins for patients who receive aneurysm repair. I
would also like to personally thank the authors for providing in
advance a copy of the manuscript.
These ﬁndings that statin use is variable across different pop-
ulations, and, additionally, that it is an independent predictor of
survival adds to the growing body of literature emphasizing the
importance of optimal medical management for patients with
surgical vascular disease. Other studies have shown that cardiovas-
cular risk reduction is not offered to many of the surgical patients
with cardiovascular disease, and perhaps this study will highlight
the importance of providing more complete care to our vascular
patients who, as a rule, have signiﬁcant coexisting disease.
I have three questions. First, your study showed improved
survival even after controlling for underlying cardiovascular
disease, suggesting that the statins may exert their effect beyondthat of reducing death associated with cardiovascular disease. Do
you think that this is likely a direct effect, or do you think that
perhaps patients receiving statins are also more likely to receive
better general care, for example, routine visits, cancer screening,
and so forth?
Second, I’m wondering if you could elaborate a little more
about the causes of death. In the manuscript, you described that
about 20% of the deaths were attributed to either aneurysm-related
causes or cardiovascular disease. How many of the remaining 80%
were due to actual other causes and for how many were the causes
not available because the deaths were collected from SSDI and
therefore unknown? Do you think having more complete informa-
tion regarding the cause of death would change your results?
My ﬁnal question is, had you considered including aneurysm
size in your analysis? Your institution has published on the feasi-
bility of repairing small aneurysms, and other authors have sug-
gested that there is a link between aneurysm size and mortality.
It might be valuable to include this variable in your analysis.
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Volume 58, Number 2 Parmar et al 363Once again, thank you to the PVS and the authors. I look
forward to your thoughts.
Dr Gaurav M. Parmar. Thank you so much for your really
important comments.
Number one is the role of statins on abdominal aortic aneu-
rysms. It is thought that the effects of statins are through usual
atherosclerotic route by inhibiting HMG-Co-A reductase. There
are relatively fewer studies that address other pathophysiologic
mechanisms. There are a couple of clinical trials that tried to demon-
strate the pleiotropic effects of statins on aortic wall stress by using
different markers, but the evidence is iffy; it’s not conclusive.
The second point, yes, about 20% of our deaths were attrib-
uted to aneurysm or cardiovascular events. Most of the remaining
deaths either come from SSDI or are due to cancer or causes
grouped as others. I would be very happy to provide the entire
distribution of our causes of death. Using SSDI to identify deaths
is a limitation of our study, and we do not have any other way to
ascertain cause of death on those deaths. But still it is reasonable to
attribute such a large mortality beneﬁt effects to use of LMDT.
Third, aneurysm size; unfortunately, we did not look at aneu-
rysm size in this analysis. I think that is an important consideration
and we will look forward to that.Dr James Reeves (Atlanta, Ga). I have one question. How
do you at UAB handle initiating statin therapy on these patients?
Do you initiate it yourself, or do you have a vascular medicine
specialist in your department who follows these patients? If you
do initiate it yourself, how do you follow the side effects, any
adverse events, or titrate the dose?
Dr Parmar. We do have vascular medicine physicians at our
institution. As I said, we don’t know about when the lipid manage-
ment was actively initiated. It could have been initiated by the
primary care practitioner earlier, at the time of surgery by our
group, or during postoperative follow-up visits.
Dr Mark A. Patterson. Thank you Dr Reeves, as one of the
authors, I can address that.
At UAB, we have two vascular medicine physicians that assist
with perioperative and postoperative medical management. If
patients are not taking statins at the initial visit, those gentlemen
become involved, and oftentimes initiate statins. That is not me
the surgeon, but us the team. Speciﬁc communication is sent to
the primary care doctor. I must say that it is uncommon for us
to get a referral from either a UAB or outside physician, in which
the patient is not already on a statin regimen. Unfortunately, I
don’t have a speciﬁc number, but it is not very large.
